CAMBISeq: Next-generation sequencing (NGS) cancer testing

Predict immunotherapy & conventional cancer therapy response

CAMBISeq (Cancer Analysis Mutational Burden Instability Sequencing) is an advanced liquid biopsy test that provides next-generation sequencing (NGS) analysis on both DNA and RNA. This NGS testing method enables the use of genomic insights to support individualized cancer treatment.

The CAMBISeq test analyzes over 500 genes that our scientists use as biomarkers to assess their sensitivity to immunotherapy or targeted therapy, supporting fully personalized oncology care. By delivering these detailed insights into a patient’s tumor, the test from RGCC helps clinicians tailor more precise and effective cancer treatment strategies. For example, it can help clinicians select the most appropriate immunotherapy and minimize the side effects of an immunotherapy.

How does the CAMBISeq test work?

Through a blood sample, the CAMBISeq test detects genetic variants across more than 500 genes. These genes serve as biomarkers that help determine sensitivity to specific treatment options.

The cancer blood test is highly sensitive and capable of detecting rare mutations, providing valuable information on the potential response to immunotherapy and targeted therapies.

The CAMBISeq test uses the TruSight™ Oncology 500 (TSO500), a targeted next-generation sequencing (NGS) assay with hybrid-capture technology. It uses unique molecular identifiers (UMIs) to detect cancer-related genetic variants in tumor samples with high sensitivity, even at low variant allele frequencies (VAFs).

It also measures key biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB).

Who should get a CAMBISeq test?

CAMBISeq is suitable for all patients with a confirmed cancer diagnosis, especially:

• Patients who have exhausted first-line therapies
• Patients seeking guidance on immunotherapy or targeted therapy
• Patients seeking personalized or precision-based treatment